본문 바로가기

Is it worth carrying out ultrasound-magnetic resonance imaging fusion targeted biopsy on Prostate Imaging Reporting and Data System score 3 prostate lesions?

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
INTERNATIONAL JOURNAL OF UROLOGY27(5) · pp.431 · 2020
피인용
Web of Science 1Scopus 1
FWCI (Scopus)
0
JCR IF
JCR 2019 2.445
ISSN
0919-8172

저자

  1. 김경환제1저자Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
  2. 구자윤Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
  3. 박원영Department of Pathology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
  4. 홍승백Department of Radiology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
  5. 김석Department of Radiology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea
  6. 하홍구교신저자Biomedical Research Institute, Pusan National University Hospital, Busan, Korea

초록

Objectives To evaluate the use of ultrasound-magnetic resonance imaging fusion targeted biopsy for Prostate Imaging Reporting and Data System 3 prostate lesions. Methods We identified 227 patients with prostate-specific antigen levels >= 4 ng/mL who underwent concurrent transrectal ultrasound-guided systemic biopsy and fusion biopsy. Suspicious prostatic lesions were assessed in accordance with Prostate Imaging Reporting and Data System version 2.0. We compared ultrasound-magnetic resonance imaging fusion targeted biopsy and ultrasound-guided biopsy cancer detection rates in Prostate Imaging Reporting and Data System 3 lesions with those in other Prostate Imaging Reporting and Data System score lesions. In Prostate Imaging Reporting and Data System 3 patients, we identified clinically significant prostate cancer risk factors by logistic regression analysis. Results In total, 2770 transrectal ultrasound-guided and 867 fusion biopsy cores were obtained; where 332 (12.0%) and 194 (22.4%) cores were prostate cancer-positive, respectively (P < 0.001). The fusion biopsy cancer detection rate (8.0%) in Prostate Imaging Reporting and Data System 3 lesions was similar to that in Prostate Imaging Reporting and Data System 1-2 lesions, but was lower than that of Prostate Imaging Reporting and Data System 4 (30.0%; P < 0.001) and 5 lesions (65.2%; P < 0.001), and ultrasound-guided biopsy (12.0%; P = 0.023). For clinically significant prostate cancer detection, fusion biopsy in Prostate Imaging Reporting and Data System 3 lesions was inferior to that in Prostate Imaging Reporting and Data System 4 and 5 lesions, and non-superior to ultrasound-guided biopsy. Cancer detection rate trends were similar in biopsy-naive patients. In Prostate Imaging Reporting and Data System 3 patients, prostate-specific antigen density was the only significant predictor of clinically significant prostate cancer. Conclusions The present findings do not support the use of ultrasound-magnetic resonance imaging fusion targeted biopsy for Prostate Imaging Reporting and Data System 3 lesions. Thus, we recommend the use of transrectal ultrasound-guided systemic biopsy for patients with Prostate Imaging Reporting and Data System 3 index lesions.

키워드

biopsydiagnosismagnetic resonance imagingprostate cancerultrasonographyDIAGNOSTIC-ACCURACYRISK STRATIFICATIONEQUIVOCAL LESIONSCANCER DETECTIONGUIDED BIOPSYVERSION 2MRICATEGORY

식별자

Scopus EID
2-s2.0-85081985956
WoS UID
000520277200001